ESMO-Virtual-Plenary-September-2023-1000x250-AACR-date

Start date: 14 Sep 2023
End date: 15 Sep 2023
Location: Virtual Meeting

Health-related quality of life (HRQoL) in the phase III NATALEE study of adjuvant ribociclib (RIB) plus a nonsteroidal aromatase inhibitor (NSAI) vs NSAI alone in patients (pts) with HR+/HER2− early breast cancer (EBC)

Thursday, 14 September 2023

Friday, 15 September 2023

18:30-19:30 CEST

13:00-14:10 CEST

Programme

Welcome and introduction, Scientific background and context
Sara Tolaney, Dana Farber Cancer Institute, Boston, MA, USA

Health-related quality of life (HRQoL) in the phase III NATALEE study of adjuvant ribociclib (RIB) plus a nonsteroidal aromatase inhibitor (NSAI) vs NSAI alone in patients (pts) with HR+/HER2− early breast cancer (EBC)
Peter Fasching, Universitätsklinikum Erlangen, Erlangen, Germany

Critical analysis and perspectives
Michail Ignatiadis, Institute Jules Bordet, Brussels, Belgium

AACR expert commentary
Stephen Johnston, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, UK

Discussion and Q&A (i)
Faculty and online audience

Programme

Virtual Plenary Expert Insights: Webcast of 14 September presentations, Discussion and Q&A (ii)
Faculty and online audience

Chair: Elaine Lim, NCCS - National Cancer Centre Singapore, Singapore

Peter Fasching, Universitätsklinikum Erlangen, Erlangen, Germany

Hiroji Iwata, Aichi Cancer Center Hospital, Nagoya, Japan

Zeifei Jiang, 307th Hospital of PLA (AMMS China), Beijing, China

Yeon Hee Park, Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul, Republic of Korea

Health-related quality of life (HRQoL) in the phase III NATALEE study of adjuvant ribociclib (RIB) plus a nonsteroidal aromatase inhibitor (NSAI) vs NSAI alone in patients (pts) with HR+/HER2− early breast cancer (EBC)

Meeting resources

You may also be interested in...